SILEXION THERAPEUTICS CORP (SLXN) Stock Price, Quote, News and Overview
NASDAQ:SLXN - Nasdaq - KYG1281K1224 - Common Stock - Currency: USD
SLXN Quote, Performance and Key Statistics
1
0 (0%)
The current stock price of SLXN is 1 USD. In the past month the price increased by 6.38%.
SLXN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About SLXN
Company Profile
Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The firm is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Company Info
SILEXION THERAPEUTICS CORP
12 Abba Hillel Road
Ramat Gan IL
Employees: 11
Phone: 97286286005
SILEXION THERAPEUTICS CORP / SLXN FAQ
What is the stock price of SILEXION THERAPEUTICS CORP today?
The current stock price of SLXN is 1 USD.
What is the ticker symbol for SILEXION THERAPEUTICS CORP stock?
The exchange symbol of SILEXION THERAPEUTICS CORP is SLXN and it is listed on the Nasdaq exchange.
On which exchange is SLXN stock listed?
SLXN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SILEXION THERAPEUTICS CORP stock?
7 analysts have analysed SLXN and the average price target is 5.1 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1. Check the SILEXION THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SILEXION THERAPEUTICS CORP worth?
SILEXION THERAPEUTICS CORP (SLXN) has a market capitalization of 8.69M USD. This makes SLXN a Nano Cap stock.
How many employees does SILEXION THERAPEUTICS CORP have?
SILEXION THERAPEUTICS CORP (SLXN) currently has 11 employees.
What are the support and resistance levels for SILEXION THERAPEUTICS CORP (SLXN) stock?
SILEXION THERAPEUTICS CORP (SLXN) has a support level at 0.91 and a resistance level at 1.04. Check the full technical report for a detailed analysis of SLXN support and resistance levels.
Should I buy SILEXION THERAPEUTICS CORP (SLXN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLXN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLXN, evaluating the profitability, health, valuation and growth aspects
- SILEXION THERAPEUTICS CORP (SLXN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SILEXION THERAPEUTICS CORP (SLXN) Sales and EPS estimates to see what analysts future expectations are.
- SILEXION THERAPEUTICS CORP (SLXN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SILEXION THERAPEUTICS CORP (SLXN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SILEXION THERAPEUTICS CORP (SLXN) Stock Chart to make your own analysis
- SILEXION THERAPEUTICS CORP (SLXN) Latest news and press-releases to stay up to date.
Does SILEXION THERAPEUTICS CORP (SLXN) stock pay dividends?
SLXN does not pay a dividend.
What is the Price/Earnings (PE) ratio of SILEXION THERAPEUTICS CORP (SLXN)?
SILEXION THERAPEUTICS CORP (SLXN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.39).
What is the Short Interest ratio of SILEXION THERAPEUTICS CORP (SLXN) stock?
The outstanding short interest for SILEXION THERAPEUTICS CORP (SLXN) is 3.27% of its float. Check the ownership tab for more information on the SLXN short interest.
SLXN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to SLXN.
SLXN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SLXN. While SLXN seems to be doing ok healthwise, there are quite some concerns on its profitability.
SLXN Financial Highlights
Over the last trailing twelve months SLXN reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS decreased by -1360.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.85% | ||
| ROE | -20.8% | ||
| Debt/Equity | 0 |
SLXN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SLXN. The Buy consensus is the average rating of analysts ratings from 7 analysts.